| Revenue growth | ~US$2bn consolidated revenue target as of FY26. |
|---|---|
| Margins | Targeting >70% revenue contribution from higher-margin Branded portfolio by FY30e. |
| Demand visibility | High in core areas: Respiratory, Dermatology, and Oncology. |
| Management confidence | Strong focus on 'Redefining the Future' via innovative oncology/biologics. |
Growth
Projected peak sales for RYALTRIS at US$250-300mn; total innovative brand annual peak sales estimated at US$700-800mn.
Outlook
Targeting 1 IND filing annually from FY27; commercializing 1-2 multispecific innovative products by 2030-2035.
Risks
Macro-economic shifts, currency fluctuations, regulatory changes in pharma, and R&D failure in clinical development.
Earnings Call filed with BSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,282.30
- Market cap
- ₹64,412 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 35.8×Sector 47.3×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.